P-491: Intervention with rosiglitazone, a PPAR-γ agonist in Brazilian obese subjects: effects on lipid profile and glucose tolerance

• Published in: American journal of hypertension Vol. 17; no. S1; p. 212A
• Main Authors: Barroso, Sergio G., Duarte, Stenio F.P., Rodrigues, Maria L.G., Sanjuliani, Antonio F., Abreu, Virginia G., Pimentel, Marcia M.G., Francischetti, Emilio A.
• Format: Journal Article
• Language: English
• Published: Oxford University Press 01.08.2004
• Subjects: Glucose Intolerance; Hypertension; Obesity
• ISSN: 0895-7061; 1941-7225; 1879-1905
• DOI: 10.1016/j.amjhyper.2004.03.565

This study was conducted to observe the effects of rosiglitazone, a PPAR-γ agonist of, on lipid profile and glucose tolerance in Brazilian obese subjects, and its relation to PPAR-γ2 Pro12Ala polymorphism. 17 obese hypertensive patients [4 males, 13 females, age = 52.6±1.4 yrs, BMI=34.9±1.1 kg/m2, mean blood pressure (MBP)=109.4±2.53 mmHg] were followed during 6 months, receiving rosiglitazone 8 mg/day. The lipid profile, fasting glucose and the 2 hour plasma glucose after 75 g of or glucose challenge were analyzed before and after the intervention. Paired T-test or the Wilcoxon matched pairs test were used when appropriate. Genomic DNA was extracted from the buffy coat obtained from 10 ml EDTA blood using standard methods from 17 adult Brazilian obese subjects from Rio de Janeiro area, and it was used for the polymerase chain reaction (PCR-RFLP). The PCR products were digested with the enzyme BstU-1 during 3h at 60°C. The digested samples were separated by electrophoresis through an 8% polyacrilamide gel and visualized by staining with silver nitrate. Our patients showed a significant gain of weight during the 24-week treatment (BMI of 34.9±1.1 to 36.0±1.2, p=0.003), without differences concerning waist circumference (103.9±2.5 to 103.3±2.8, p=0.6). Besides the weight gain, the patients experienced a blood pressure reduction, but we found statistical significance only for systolic blood pressure [148.8±2.8 to 136.9±2.4 (p=0.002)].We haven't observed differences on lipid profile [Triglycerides: 147.0±15.8 to 165.6±33.0 mg/dl (p=0.39), HDL-cholesterol: 45.2±4.1 to 42.9±2.5 mg/dl (p=0.27), LDL-cholesterol: 135.2±10.8 to 143.0±11.3 mg/dl (p=0.23). The 2 hour oral glucose tolerance test presented a significant difference after the intervention [141.0±14.3 to 112.9±10.0 mg/dl (p<0.05)], but not of fasting glucose. Among our patients there were two subjects with the PPAR-γ2 Pro12Ala polymorphism. Although rosiglitazone increased body weight in our patients, it appears to be effective on improving glucose tolerance and the blood pressure control. This project was supported by Grant-in-Aid from Glaxo-Wellcome and Internal Medical Assistance Limited -AMIL. Am J Hypertens (2004) 17, 212A–212A; doi: 10.1016/j.amjhyper.2004.03.565